Elderly patients In a study comparing single and multiple-dose pharmacokinetic profiles of intravenous methylnaltrexone at a dose of 24 mg between healthy, young (18 to 45 years of age n=10) and elderly (65 years of age and over n=10) subjects, the effect of age on exposure to methylnaltrexone was found to be minor.